{"id":13142,"date":"2025-08-23T12:00:00","date_gmt":"2025-08-23T16:00:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=13142"},"modified":"2025-08-21T14:47:42","modified_gmt":"2025-08-21T18:47:42","slug":"%e2%9d%84%ef%b8%8f-covid-19-and-chilblains-unraveling-the-dermatologic-puzzle-in-2025","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=13142","title":{"rendered":"\u2744\ufe0f COVID-19 and Chilblains: Unraveling the Dermatologic Puzzle in 2025"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">\ud83d\udd2c Overview<\/h3>\n\n\n\n<p>As the COVID-19 pandemic enters its fifth year, dermatological manifestations remain a key area of clinical and immunological inquiry. Among these, chilblains\u2014also known as pernio\u2014have emerged as a peculiar and persistent phenomenon, often dubbed \u201cCOVID toes\u201d in early reports. Recent studies published in 2025 continue to refine our understanding of their pathogenesis, epidemiology, and diagnostic implications.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83e\uddec Pathophysiology: The Interferon Connection<\/h3>\n\n\n\n<p>One of the most compelling insights from recent literature is the role of type I interferon responses in COVID-associated chilblains. Histopathological studies have identified elevated levels of myxovirus resistance protein 1 (MxA), an interferon-induced GTPase, in both COVID-related chilblains and chilblain lupus. This suggests a shared immunologic pathway, where a robust innate response may suppress viral replication but trigger localized vascular inflammation.<\/p>\n\n\n\n<p>Key mechanisms include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Interferon \u03b1 overexpression<\/strong>: Linked to reduced PCR\/antibody positivity, complicating diagnosis<\/li>\n\n\n\n<li><strong>Endothelial dysfunction<\/strong>: SARS-CoV-2 may indirectly damage microvasculature, leading to pernio-like lesions<\/li>\n\n\n\n<li><strong>ACE2 receptor modulation<\/strong>: Chilblains may reflect downstream effects of viral interaction with ACE2 and JAK-STAT pathways<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83d\udcca Epidemiological Trendsffff<\/h3>\n\n\n\n<p>A 2025 update in the <em>British Journal of Dermatology<\/em> highlights that pseudo-chilblains were among the earliest dermatologic signs observed during the pandemic, particularly in younger, otherwise asymptomatic individuals. However, longitudinal data show that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Chilblains were not strongly correlated with regional COVID-19 case surges (Spearman coefficient 0.18)<\/li>\n\n\n\n<li>Latinx populations had disproportionately fewer chilblain cases despite higher COVID-19 incidence, suggesting behavioral or genetic modifiers<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83e\uddea Diagnostic Challenges<\/h3>\n\n\n\n<p>The interferon-driven nature of COVID-related chilblains presents a diagnostic paradox:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patients often test negative via PCR or serology due to suppressed viral replication<\/li>\n\n\n\n<li>Emerging biomarkers like lymphocyte activation assays may offer more sensitive detection, though they remain experimental<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83d\udc89 Post-Vaccine and Long COVID Considerations<\/h3>\n\n\n\n<p>Cutaneous manifestations, including recurrent chilblains, have been reported post-vaccination and in long COVID syndromes. These may reflect lingering immune dysregulation or vaccine-triggered interferon responses.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83e\udde0 Implications for Practice and Research<\/h3>\n\n\n\n<p>The chilblains-COVID link underscores the need for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Broader diagnostic criteria beyond PCR\/antibody testing<\/li>\n\n\n\n<li>Continued exploration of interferon biology in viral and autoimmune dermatology<\/li>\n\n\n\n<li>Culturally sensitive epidemiologic modeling to account for behavioral and socioeconomic factors<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83e\uddec Pathogenesis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Type I Interferon Hyperactivation<\/strong> Triggered via TLR7 in plasmacytoid dendritic cells (pDCs), leading to sterilizing immunity and acral inflammation<\/li>\n\n\n\n<li><strong>Endothelial Dysfunction<\/strong> Microvascular damage and inflammation contribute to lesion formation<\/li>\n\n\n\n<li><strong>ACE2 Receptor Modulation<\/strong> Alters vascular tone and immune signaling, possibly amplifying pernio-like symptoms<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83d\udcca Epidemiology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Chilblains surged during early COVID waves, especially in youth<\/li>\n\n\n\n<li>Often appeared in mild or asymptomatic cases<\/li>\n\n\n\n<li>Seasonal clustering observed, with lower incidence in Latinx populations despite higher COVID rates<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83e\uddea Diagnostic Challenges<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Many patients show no seroconversion or PCR positivity<\/li>\n\n\n\n<li>Histopathology reveals MxA protein and pDC infiltration<\/li>\n\n\n\n<li>Chilblains may reflect strong innate immunity rather than active infection<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83d\udd0d Implications for Practice &amp; Research<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Chilblains could serve as a biomarker for robust interferon response<\/li>\n\n\n\n<li>Calls for broader diagnostic criteria beyond PCR\/antibody tests<\/li>\n\n\n\n<li>Future research should explore genetic predisposition and immune modulation strategies<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ud83d\udd2c Overview As the COVID-19 pandemic enters its fifth year, dermatological manifestations remain a key area of clinical and immunological inquiry. Among these, chilblains\u2014also known as pernio\u2014have emerged as a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":13145,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,82,144,257,972,973,607,608],"tags":[],"class_list":["post-13142","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ace2-agonist","category-chilblains","category-endothelium","category-interferon","category-vaccine-enhanced-disease","category-vaccine-failure","category-vaccine-news","category-vaccine-safety"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/13142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13142"}],"version-history":[{"count":3,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/13142\/revisions"}],"predecessor-version":[{"id":13148,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/13142\/revisions\/13148"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/13145"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}